Lexeo Therapeutics, Inc. · NASDAQ:LXEO
Lexeo Therapeutics — Technical Presentation (November 2026)
21 slides from Lexeo Therapeutics's technical presentation, Nov 16, 2026
Slide 1: Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020
Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 in PKP2 Arrhythmogenic Cardiomyopathy November 16, 2026 Exhibit 99.2 1
Slide 2: Forward-looking statements
Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product
Slide 3: Interim LX2020 data demonstrate clinically meaningful reductions in severe arrhythmia burden
CLINICAL EFFICACY 80% mean reduction in NSVT and 44% mean reduction in PVC burden at latest assessment in participants in high-dose cohorts (n=7) Deepening reduction in mean NSVT burden over time in high-dose cohorts 5 of 7 participants in high-dose cohorts reported symptom improvement on PGIC scale
Slide 4: Significant commercial potential for LX2020 given unmet need and global patient population
Significant commercial potential for LX2020 given unmet need and global patient population 60K Patients in the U.S. >$4-6B Total addressable market opportunity Larger-rare, diagnosed population Significant commercial upside at peak Trial ready Broad patient pool expected to support rapid recruitment
Slide 5: Treatment response in PKP2-ACM may be reflected across complementary measures of disease activity
Treatment response in PKP2-ACM may be reflected across complementary measures of disease activity ACM, arrhythmogenic cardiomyopathy; PVC, premature ventricular contraction; NSVT, non-sustained ventricular tachycardia; VA, ventricular arrhythmia; ICD, implantable cardioverter defibrillator; RVEF, ri
Slide 6: Ventricular arrhythmic activity exists along a spectrum of increasing complexity and clinical consequence
Ventricular arrhythmic activity exists along a spectrum of increasing complexity and clinical consequence Non-sustained Ventricular Tachycardia (NSVT) Three or more consecutive ventricular beats lasting < 30 seconds at a ventricular rate of > 100 bpm1 Indicates increased ventricular electrical insta
Slide 7: NSVT history and incidence is high among ACM patients with ICDs
NSVT history and incidence is high among ACM patients with ICDs Arrhythmia Burden NSVT-ASSOCIATED ICD IMPLANTATION NSVT IS AN ESTABLISHED THRESHOLD FOR ICD DECISIONS ~1.7x higher rate of ICD implantation in patients with a history of NSVT1 NSVT is a clinically relevant marker included in major ACM r
Slide 8: Ejection fraction and RV free wall strain provide complementary views of systolic function in ACM
Ejection fraction and RV free wall strain provide complementary views of systolic function in ACM Ejection fraction (EF) Pump output Percentage of ventricular blood volume ejected with each contraction of the RV or LV Global measure of systolic function EF may remain stable in early ACM LVEF largely
Slide 9: LX2020 is being evaluated in an ongoing Phase 1/2 study: HEROIC-PKP2
LX2020 is being evaluated in an ongoing Phase 1/2 study: HEROIC-PKP2 2 Key Inclusion Criteria Adults (18-65 years) Diagnosis of ACM with documented PKP2 mutation Existing ICD that is MRI compatible Minimum threshold of PVCs/24-hr Neutralizing anti-AAVrh.10 titer cutoff 1 Study Design & Objective Des
Slide 10: Baseline characteristics consistent with PKP2-ACM, with more severe arrhythmia burden in high-dose cohorts
Baseline characteristics consistent with PKP2-ACM, with more severe arrhythmia burden in high-dose cohorts Cohort 1 (2.0x1013 vg/kg) Cohorts 2 & 3 (6.0x1013 vg/kg) Participant 1 2 3 4 5 6 7 84 9 10 Age, years 34 22 29 44 43 30 41 41 28 39 Age at diagnosis 27 21 28 29 28 27 30 34 16 37 Gender M M M M
Slide 11: In high-dose cohorts, 80% mean improvement in NSVT and 44% mean improvement in PVCs
In high-dose cohorts, 80% mean improvement in NSVT and 44% mean improvement in PVCs at latest assessment Cohort Part. # Latest Visit1 (months) ∆ PVC / 24H Baseline → LV ∆ NSVT / 7d Baseline → LV ∆ RVEF %1 Baseline → LV ∆ RV Strain %1 Baseline → LV ∆ PGIC Scale Baseline LV Low Dose Cohort 1 (2E13 v
Slide 12: Deepening reduction in NSVT observed, while natural history shows increased arrhythmic burden
n=3 n=7 n=3 n=6 n=2 n=2 n=1 n=7 n=15 n=6 Deepening reduction in NSVT observed, while natural history shows progressively increased arrhythmic burden Mean NSVT Change: NSVT / 7d NSVT / 7d Deepening NSVT reduction over time with 80% mean reduction at latest visit in high-dose cohorts (n=7) In contrast
Slide 13: 83% of high-dose cohort had less than 1 NSVT per day at 12 months
83% of high-dose cohort had less than 1 NSVT per day at 12 months, a clinically relevant threshold for ACM management n=6 n=2 n=7 n=15 % Participants with Significant NSVT Burden (at least 7 NSVT / 7d; High-dose Cohort) ≥7 NSVT / 7d The presence of NSVT is a clinically relevant marker for risk strat
Slide 14: 100% of high-dose participants below clinically relevant NSVT threshold at latest Holter
100% of high-dose participants were below the clinically relevant threshold for NSVT (<1/day) at latest Holter NSVT Change: NSVT / 7d Baseline 6 Mo (n=7) 9 Mo (n=7) 12 Mo (n=6) 18 Mo (n=2) Mean change from baseline - +5% -31% -56% -59% Participants below 1 NSVT/day (<7/7d) 2/7 29% 5/7 71% 4/7 57% 5/
Slide 15: LX2020 reduced mean PVC burden by 44% in high-dose cohorts at latest assessment
n=3 n=7 n=6 n=2 n=1 n=2 n=3 n=7 n=6 n=15 LX2020 reduced mean PVC burden by 44% in high-dose cohorts at latest assessment Mean PVC Change: Mean PVC Change: PVC / 24h PVC / 24h Mean PVC count decreased 44% at latest assessment across participants in high-dose cohorts (n=7) In contrast, participants in
Slide 16: Evidence of improved systolic function with RV free wall strain improvements and EF stabilization
Evidence of improved systolic function with RV free wall strain improvements and EF stabilization n=3 n=7 n=4 n=3 Improvement Mean RV Wall Strain: RV Wall Strain % RV free wall longitudinal strain, assessed via cardiac MRI, measures the percentage shortening of the RV free wall during systole RV wal
Slide 17: Supportive findings from cardiac biopsy and ECG
Supportive findings from cardiac biopsy and ECG LX2020 not detected in pre-dose VCN or mRNA samples as expected. Participant 3 elected not to undergo a post-treatment biopsy. Participant 1 VCN not performed due to insufficient remaining cardiac biopsy tissue following other analyses. GAPDH normalize
Slide 18: Safety update: Treatment with LX2020 generally well tolerated to date
Safety update: Treatment with LX2020 generally well tolerated to date LX2020 generally well tolerated across 10 participants dosed No clinically significant complement activation No study discontinuations Previously disclosed LFT elevations observed in high-dose cohorts were successfully managed per
Slide 19: Summary of results and next steps for LX2020
Summary of results and next steps for LX2020 Meaningful Clinical Activity LX2020 continues to demonstrate improvements across multiple measures of disease burden and patient experience Increasing Confidence in Dataset Additional follow-up strengthens the durability, consistency, and overall benefit-
Slide 20: Thank you to the ACM community
Thank you to the ACM community Individuals and families impacted by genetically mediated cardiovascular diseases are at the center of our mission We are grateful to the participants, caregivers, investigators, advocacy organizations and broader ACM community who contributed to HEROIC-PKP2 We remain
Slide 21: Thank you
Thank you
Lexeo Therapeutics — Technical Presentation (November 2026) on 6ix